Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Current assets:
Cash and cash equivalents	$ 3,627	$ 5,858
Prepaid expenses and other assets	489	507
Research and Development (“R&D”) tax incentive receivable	11,093	9,837
Total current assets	15,209	16,202
Property, plant and equipment, net	428	472
Operating lease right-of-use assets	411	373
Total assets	16,048	17,047
Current liabilities:
Trade and other payables	1,555	612
Accrued expenses and other current liabilities	7,487	4,845
Operating lease liabilities, current	190	163
Total current liabilities	9,232	5,620
Operating lease liabilities, non-current	221	210
Total liabilities	9,453	5,830
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common Stock, $0.0001 par value per share – 100,000,000 shares authorized; 17,642,832 and 17,642,832 shares issued and outstanding at September 30, 2024 and June 30, 2024, respectively	2	2
Preferred Stock, $0.0001 par value per share, 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2024 and June 30, 2024, respectively
Additional paid-in capital	125,677	125,218
Accumulated deficit	(116,091)	(110,671)
Foreign currency translation reserve	(2,993)	(3,332)
Total stockholders’ equity	6,595	11,217
Total liabilities and stockholders’ equity	$ 16,048	$ 17,047